PsychoTropicalResearch, serotonin and serotonin syndrome research.

1. Gillman, PK. Mechanisms, management and measurement in atropine induced hyperthermia. Anaesth Intensive Care 37(2): p. 322-323. 2009.
Original Paper.

2. Stanford, SC, Stanford, BJ, and Gillman, PK. Risk of severe serotonin toxicity following co-administration of methylene blue and serotonin reuptake inhibitors: an update on a case report of post-operative delirium.. J Psychopharmacol (Oxf), 2009: p. [Epub ahead of print] doi:10.1177/0269881109105450.. 2009.
In Preparation. E-publication.

3. Gillman, PK. Is there sufficient evidence to suggest cyclobenzaprine might be implicated in causing serotonin toxicity?. Am. J. Emerg. Med 27: p. 509-510.. 2009.
Original Paper.

4. Schwiebert, C, Irving, C, and Gillman, PK. Small doses of methylene blue, previously considered safe, can precipitate serotonin toxicity. Anaesthesia 64: p. 924-924 . 2009.
Original Paper.

5. Gillman, PK. Fentanyl and serotonin toxicity. Br. J. Anaesth. 2009.
Original Paper. E-publication.
View article for free

6. Gillman, PK. Lessons continue: serotonin toxicity. Consult Pharm 24: p. 398-399 . 2009.
Original Paper.

7. Gillman, PK. CNS toxicity involving methylene blue: the exemplar for understanding and predicting drug interactions that precipitate serotonin toxicity. J Psychopharmacol (Oxf) p. 2009.
In Press.

8. Gillman, PK. Triptans, Serotonin Agonists, And Serotonin Syndrome (Serotonin Toxicity): A Review. Headache p. 2009.
In Press.

9. Gillman, PK. The nature of hyperthermia in neuroleptic malignant syndrome and the use of bromocriptine. Journal of Medical Toxicology p. 2009.
In Press.

10. Gillman, PK. Myths about MAOIs uncritically perpetuated. Aust. N. Z. J. Psychiatry p. 2009.
In Press.

11. Gillman, PK. Guidelines on Methylene blue and serotonin toxicity.. Laryngoscope p. 2009.
In Press.

12. Gillman, PK. Methylene Blue: A Risk for Serotonin Toxicity. ANZCA Bull 17(-): p. 36. 2008.
In Press. Original Paper.

13. Gillman, PK. Methylene blue is a potent monoamine oxidase inhibitor. Can. J. Anaesth 55(5): p. 311-2.. 2008.
In Press. Original Paper.

14. Gillman, PK. Serotonin toxicity. . Headache 48(4): p. 640-1. 2008.
Original Paper.

15. Gillman, PK . Tricyclic antidepressant pharmacology and therapeutic drug interactions updated. British Journal of Pharmacology. 2007.
Major Review. Major Overview. E-publication.
View article for free

16. Rona R. Ramsay, Catherine Dunford and Ken Gillman. Methylene Blue and Serotonin Toxicity: Inhibition of MAO A confirms a Theoretical Prediction. Publisher to be anounced. 2007.
In Preparation. Original Paper.

17. Peterson, G, Jackson, S, Mark Naunton, M, Gillman, PK. Beware of anticholinergics in the elderly: delirious dangers of the deadly nightshade. Journal of Pharmacy. 2006.
Review.

18. Naunton, M, Gillman, PK. Pharmacy students and 'Big Pharma'. 25: p. 562-583.. Australian Pharmacist. 2006.
Letter.

19. Lawrence, KR, Adra, M, Gillman, PK. Serotonin Toxicity Associated with the Use of Linezolid: A Review of Postmarketing Data. Clinical Infectious Diseases. 42: p. 1578-1583. 2006.
Original Paper.
View article for free

20. Gillman, PK. Methylene Blue implicated in potentially fatal serotonin toxicity. Anaesthesia. 61: p. 1013-1014. 2006.
Case Report. Comment.

21. Gillman, PK. Psychotic depression and 'multi-aminergic' treatment strategies. British Journal of Psychiatry: p.???. 2006.
Short Report. E-publication.
View article for free

22. Gillman, PK. Pharmaceutical company influence. Public Library of Science: Medicine. 2(12): p. e392. 2006.
Letter.
View article for free

23. Gillman, PK. Disease mongering: one of the hidden consequences. Public Library of Science: Medicine. 3(7): p. e316. DOI: 310.1371/journal.pmed.0030316. 2006.
Letter.
View article for free

24. Gillman, PK. Deleterious cognitive effects of anti-muscarinic drugs. Australian Prescriber: p. e-copy. 2006.
Letter.
View article for free

25. Gillman, PK. A response to 'Tramadol and severe serotonin syndrome'. Anaesthesia. 61(1): p. 76. 2006.
Letter.
View article for free

26. Gillman, PK. Extracting value from case reports: lessons from Serotonin toxicity. Anaesthesia. 61: p. 419-422. 2006.
Editorial.

27. Gillman, PK. A systematic review of the serotonergic effects of mirtazapine: implications for its dual action status. Human Psychopharmacology Clinical and Experimental. 21: p. 117-125. 2006.
Major Review.
View article for free

28. Gillman, PK. A review of serotonin toxicity data: implications for the mechanisms of antidepressant drug action. Biological Psychiatry. 59: p. 1046-1051. 2006.
Major Review.
View article for free

29. Gillman, PK. Serotonin toxicity, serotonin syndrome: 2006 update, overview and analysis. . 2006.
Major Review.
View article for free

30. Gillman, PK. Drug interactions and fluoxetine: a commentary from a clinician's perspective. . 2006.
Editorial.
View article for free

31. Gillman, PK. Understanding toxidromes: serotonin toxicity. A Commentary on Montanes-Rada et al. Journal of Clinical Psychopharmacology. 2005.
Mini Review.
View article for free

32. Gillman, PK. Monoamine oxidase inhibitors, opioid analgesics and serotonin toxicity. British Journal of Anaesthesia. 2005.
Review.
View article for free

33. Gillman, PK. Serotonin toxicity, serotonin syndrome: 2005 update, overview and analysis. Psychotropical.com. 2005.
Major Overview.
View article for free

34. Gillman, PK. Misleading cases. Journal of the American Medical Directors Association. 6: p. 422-423. 2005.
Comment.
View article for free

35. Gillman, PK. The serotonin syndrome. New England Journal of Medicine. 352(23): p. 2454-2456. 2005.
Comment.
View article for free

36. Gillman, PK. Non-science and nonsense, without refutation. Public Library of Science: Medicine. 2005.
Letter.
View article for free

37. Gillman, PK. NMS and ST: chalk and cheese. British Medical Journal. 2005.
Letter.
View article for free

38. Gillman, PK. Signing the script. Australian Prescriber. 28: p. 29. 2005.
Comment.
View article for free

39. Gillman, PK. Mirtazapine: not a dual action antidepressant?. Australian and New Zealand Journal of Psychiatry 38(4): p. 266-267. 2004.
Comment.

40. Gillman, PK. Making sense of serotonin toxicity reports. A Comment on Chopra et al. World Journal of Biological Psychiatry. 5: p. 166-167. 2004.
Mini Review. Comment.

41. Gillman, PK. Moclobemide and the risk of serotonin toxicity (or serotonin syndrome). Central Nervous System Drug Reviews. 10: p. 83-85. 2004.
Review. Comment.

42. Gillman, PK. Moclobemide and the risk of serotonin toxicity (or serotonin syndrome). Central Nervous System Drug Reviews. 10: p. 83-85. 2004.
Review. Comment.

43. Gillman, PK and Whyte, IM. Serotonin syndrome. Adverse Syndromes and Psychiatric Drugs, ed. Haddad, P, Dursun, S, and Deakin. Oxford University Press. 37-49. 2004.

44. Gillman, PK. Re: no evidence of increased adverse drug reactions in cytochrome P450 CYP2D6 poor metabolizers treated with fluoxetine or nortriptyline. Human Psychopharmacology. Clinical and Experimental. 20(1): p. 61-62. 2004.
Letter.
View article for free

45. Gillman, PK. Serotonin toxicity. www.depression-webworld.com. 2004.
Mini Review.
View article for free

46. Gillman, PK. Reply to associate professor Norman. Australian and New Zealand Journal of Psychiatry. 38(4): p. 269. 2004.
Comment.
View article for free

47. Gillman, PK. Comment on "Serotonin syndrome due to coadministration of linezolid and venlafaxine" by Jones et al. Journal of Antimicrobial Chemotherapy. 54: p. 844-845. 2004.
Comment. Letter.

48. Gillman, PK. Defining toxidromes: serotonin toxicity and neuroleptic malignant syndrome: A comment on Kontaxakis et al. Archives of General Hospital Psychiatry . 2004.
Mini Review.
View article for free

49. Gillman, PK. Serotonin toxicity [electronic response to Perry NK; Venlafaxine-induced serotonin syndrome with relapse following amitriptyline]. Postgraduate Medical Journal. BMJ. 2004.
Comment.
View article for free

50. Gillman, PK. The spectrum concept of serotonin toxicity. Pain Medicine. 5: p. 231-232. 2004.
Mini Review. Comment. Letter.

51. Gillman, PK. Fifty years of poor science. British Journal of Psychiatry. 2003.
Comment.
View article for free

52. Gillman, PK. Mirtazapine: unable to induce serotonin toxicity?. Clinical Neuropharmacology. 26: p. 288-289. 2003.
Comment.
View article for free

53. Gillman, PK. Serotonin toxicity and 5-HT2A receptors. Current Psychiatry (Online). 2: p.. 2003.
Comment.
View article for free

54. Gillman, PK. Prayer study defects. Skeptical Inquirer. 23: p. 67. 2003.
Comment.

55. Gillman, PK. Serotonin syndrome. Australian Prescriber. 26: p. 100-101. 2003.
Comment.

56. Gillman, PK. Linezolid and serotonin toxicity. Clinical Infectious Diseases. 37: p. 1274-1275. 2003.
Comment.

57. Gillman, PK. Amitriptyline: Dual-Action Antidepressant?. Journal of Clinical Psychiatry. 64: p. 1391. 2003.
Comment.

58. Gillman, PK. Reply to: Clinical interview Serotonin syndrome. Australian Medicine. Oct: p. 71. 2001.
Letter.

59. Gillman, PK. Limits in drug assessment. Skeptical Inquirer. 25(4): p. 77. 2001.
Letter.

60. Gillman, PK. Cytochrome P450 enzyme interactions. Australian Prescriber. 24(4): p. 80. 2001.
Comment.

61. Gillman, PK. Clinical interview: Serotonin syndrome. Australian medicine. August: p. 5-6. 2001.
Interview.

62. Gillman, PK. Comments on "Serotonin syndrome during treatment with paroxetine and risperidone". Journal of Clinical Psychopharmacology. 21(3): p. 344-345. 2001.
Comment.
View article for free

63. Gillman, PK. Relative value of bupropion. Australian Medicine. 13: p. 7. 2001.
Letter.

64. Gillman, PK. Serotonin syndrome. Psychiatric Bulletin of the Royal College of Psychiatrists. 24: p. 197. 2000.
Letter.

65. Gillman, PK. Paradoxical pattern of haematological risk with clozapine. British Journal of Psychiatry. 177: p. 88. 2000.
Comment. Letter.

66. Gillman, PK. Commentary: clomipramine too soon after moclobemide. Review of Psychiatry. 4: p. 3-5. 1999.
Mini Review.

67. Gillman, PK. The serotonin syndrome and its treatment. Journal of Psychopharmacology. 13(1): p. 100-109. 1999.
Review.

68. Gillman, PK. Relative toxicity of antidepressants. Australian and New Zealand Journal of Psychiatry. 33: p. 444. 1999.
Comment.

69. Gillman, PK. Relative effectiveness and safety of antidepressants. Drug Wise. 23: p. 20. 1999.
Comment.

70. Gillman, PK. Serotonin Syndrome: History and Risk. Fundamental and Clinical Pharmacology. 12(5): p. 482-491. 1998.
Review.

71. Gillman, PK and Hodgens, S. Serotonin syndrome following SSRI mono-therapy. Human Psychopharmacology. Clinical and Experimental. 13: p. 525-526. 1998.
Mini Review. Letter.

72. Gillman, PK. Serotonin syndrome: clomipramine too soon after moclobemide. International Clinical Psychopharmacology. 12: p. 339-342. 1997.
Mini Review.

73. Gillman, PK. Serotonin syndrome treated with chlorpromazine. Journal of Clinical Psychopharmacology. 17: p. 128-129. 1997.
Letter.

74. Gillman, PK. Ecstasy, serotonin syndrome and the treatment of hyperpyrexia. Medical Journal of Australia. 167: p. 109-111. 1997.
Letter.

75. Gillman, PK. Tacrine for treatment of sleep disturbance in dementia. Journal of the American Geriatrics Society. 45(10): p. 1286. 1997.
Letter.

76. Gillman, PK. Scepticism about health care claims. Sceptical Inquirer. 17: p. 34. 1997.
Letter.

77. Gillman, PK. Successful treatment of serotonin syndrome with chlorpromazine. Medical Journal of Australia. 165: p. 345. 1996.
Letter.

78. Gillman, PK. Serotonin syndrome: It's older than you think. Drug Wise. 20(5): p. 59. 1996.
Comment.

79. Gillman, PK. The new antidepressants. Australian Prescriber. 19(2): p. 37-38. 1996.
Letter.

80. Gillman, PK. Possible serotonin syndrome with moclobemide and pethidine. Medical Journal of Australia. 162: p. 554. 1995.
Letter.

81. Gillman, PK. Plus ça change, plus c'est la même chose. Pharmabulletin. 18(1): p. 10-11. 1994.
Comment.

82. Gillman, PK. MAOIs and dangerousness. Australian Prescriber. 17(2): p. 29. 1994.
Letter.

83. Gillman, PK. Fluoxetine (Prozac). Medical Journal of Australia. 159(7): p. 492. 1993.
Letter.

84. Gillman, PK. Safety of MAOIs and side effects of clomipramine. Pharmabulletin. 14: p. 15. 1990.
Letter.

85. Gillman, PK. Latitude and affective disorders. British Journal of Psychiatry. 151: p. 276. 1987.
Letter.

86. Gillman, PK. Playing dice with the expert evidence. Medical Journal of Australia. 147: p. 532. 1987.
Letter.

87. Gillman, PK. Monoamineoxidase inhibitors. Current Therapeutics. 43: p. 79. 1984.
Letter.

88. Curson, DA, Trauer, T, Bridges, PK and Gillman, PK. Assessment of outcome after psychosurgery using the Present State Examination. British Journal of Psychiatry. 143: p. 118-123. 1983.
Paper.

89. Gillman, PK, Bartlett, JR, Bridges, PK, et al. Indolic substances in plasma, cerebrospinal fluid, and frontal cortex of human subjects infused with saline or tryptophan. Journal of Neurochemistry. 37(2): p. 410-417. 1981.
Paper.

90. Gillman, PK, Bartlett, J, Bridges, PK. Selecting patients for psychosurgery. Biological Psychiatry. 16: p. 1090-1094. 1981.
Paper.

91. Carter, SM, Glover, V, Sandler, M, Gillman, PK and Bridges, PK. Human platelet phenolsulphotransferase: separate control of the two forms and activity range in depressive illness. Clinica Chimica Acta. 117(3): p. 333-344. 1981.
Paper.

92. Gillman, PK, Bartlett, JR, Bridges, PK, Kantamaneni, BD and Curzon, G. Relationships between tryptophan concentrations in human plasma, cerebrospinal fluid and cerebral cortex following tryptophan infusion. Neuropharmacology. 19(12): p. 1241-1242. 1980.
Paper.

93. Curzon, G, Kantamaneni, BD, Van Boxel, P, et al. Substances related to 5-hydroxytryptamine in plasma and in lumbar and ventricular fluids of psychiatric patients. Acta Psychiatrica Scandinavica. 280: p. 3-20. 1980.
Paper.

94. Carter, S M, Goodwin, BL, Sandler, M, Gillman, PK and Bridges, PK. Decreased conjugated tyramine output in depression: the effect of oral L-cysteine. British Journal of Clinical Pharmacology. 10(3): p. 305-308. 1980.
Paper.

95. Gaind, R, Gillman, PK and Taylor, P. Alpha-methyldopa in schizophrenia. Journal of Clinical Psychiatry. 39(11): p. 815-816. 1978.
Paper.

96. Gillman, PK. The team approach. British Journal of Psychiatry. 141: p. 276. 1977.
Letter.